• NICE turns down AZ’ Daxas for COPD pharmatimes
    February 13, 2017
    The National Institute for Health and Care Excellence has rejected AstraZeneca's Daxas for use by the NHS to treat certain patients with chronic obstructive pulmonary disease (COPD).
PharmaSources Customer Service